Search Videos and More
News
Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.
News
Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds
A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.
News
New Insights into Immunotherapy Targets for Pancreatic Cancer
Cancer research often focuses on gene mutations in the parts of the human genome that produce cellular machinery called proteins. But the rest of the genome — sometimes called the “dark genome” — can also play a role.
News
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
News
Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
News
High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer
SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial of vitamin D combined with standard chemotherapy plus bevacizumab in patients with previously untreated metastatic colorectal cancer.
News
Early Action, Better Outcomes: Transforming Cancer Prevention
For more than 100 years, health advocates have spread the message that, with cancer, patience is not a virtue.
News
In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer
In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors.
News
Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them
Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse.
News
New Targeted Treatments Emerge for Gastric and Esophageal Cancer
For years, patients with advanced forms of gastric and esophageal cancer have had relatively few treatment options.
News
New Research from Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center Finds that Radiation Can Be Safely Omitted in Select Patients with Locally Advanced Rectal Cancer
New data led by researchers at Dana-Farber Brigham Cancer Center and Memorial Sloan Kettering Cancer Center (MSK) and featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in?The New England Journal of Medicine (NEJM)?and the Journal of Clinical Oncology today indicates that some patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation before surgery.
News
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma